Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

VENUS PHARMA

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000300 143 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx143product presentations
G62generic molecules
DF6dosage-form groups
TA12therapeutic areas
PKR143current price records
REG95registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage91%
priced packs safely normalized per unit
Comparable-market coverage74%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixVENUS PHARMAShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/venus-pharmaGenerated 10 Aug 2026Anti-infectives37 · 26%Gastrointestinal & hepatology22 · 15%Pain & musculoskeletal21 · 15%CNS & mental health16 · 11%Anesthesia & critical care13 · 9%Respiratory & allergy11 · 8%Cross-therapeutic & anti-inflamma…7 · 5%Other therapeutic areas16 · 11%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioVENUS PHARMADistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/venus-pharmaGenerated 10 Aug 2026143presentationsTablet79 · 55%Injection53 · 37%Capsule4 · 3%Ointment3 · 2%Cream2 · 1%Infusion2 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionVENUS PHARMACurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/venus-pharmaGenerated 10 Aug 2026106comparable productsBelow market median66 · 62%Near market median29 · 27%Above market median11 · 10%Company median price position-20.3%Lowest-price equivalents44Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsVENUS PHARMACompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/venus-pharmaGenerated 10 Aug 2026Mediate Pharmaceutical Pvt Ltd25 shared40% overlapNeutro Pharma (Pvt.) Ltd.,24 shared39% overlapZafa Pharmaceutical Laboratories (P…23 shared37% overlapSAFE PHARMACEUTICAL (PVT) LTD22 shared35% overlapMS SIZA INTERNATIONAL PVT LTD.22 shared35% overlapBosch Pharmaceuticals (Pvt) Ltd.21 shared34% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives37 products · 26%
Gastrointestinal & hepatology22 products · 15%
Pain & musculoskeletal21 products · 15%
CNS & mental health16 products · 11%
Anesthesia & critical care13 products · 9%
Respiratory & allergy11 products · 8%
Cross-therapeutic & anti-inflammatory7 products · 5%
Cardiovascular6 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Analgesics / NSAIDs20 products · 14%
Peri-operative / autonomic medicines8 products · 6%
Antimalarials7 products · 5%
Systemic corticosteroids7 products · 5%
Aminoglycoside antibacterials7 products · 5%
Antihistamines6 products · 4%
Fluoroquinolone antibacterials6 products · 4%
Benzodiazepines / sedatives6 products · 4%
Formulation footprint

Dosage forms

Tablet79 products
Injection53 products
Capsule4 products
Ointment3 products
Cream2 products
Infusion2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 DEXAMETHASONEDexamethasone 5presentations 0.5 mg, 4 mg · Tablet, Injection #2 MetroveMetronidazole (Benzoate) 5presentations 200 mg, 400 mg, 5 mg · Tablet, Injection #3 ValronDiclofenac 5presentations 25 mg, 50 mg · Injection, Tablet #4 GentamicinGentamicin 4presentations 40 mg · Injection #5 PhenobarbitalPhenobarbital 4presentations 200 mg/mL, 30 mg · Injection, Tablet #6 Vee-BufenIbuprofen 4presentations 200 mg, 400 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median6662% of comparable products
Near market median29within ±5% of median
Above market median1110% of comparable products
Lowest-price equivalents44ties included
Company median price position -20.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Gentamicin 40 mgGentamicin · Injection · 25ml PKR 0.68/mL-96.0% vs market median DEXAMETHASONE 4 mgDexamethasone · Injection · 30ml PKR 1.72/mL-90.3% vs market median Viodol 500 mgParacetamol · Tablet · 200’s PKR 0.68/tablet-80.8% vs market median Viopam-5 5 mgDiazepam · Tablet · 1000’s PKR 0.27/tablet-79.9% vs market median DEXAMETHASONE 4 mgDexamethasone · Injection · 5ml PKR 3.80/mL-78.6% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 25shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 24shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 23shared generics SAFE PHARMACEUTICAL (PVT) LTD137 products · 53 generics 22shared generics MS SIZA INTERNATIONAL PVT LTD.128 products · 63 generics 22shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 21shared generics
Regulatory & price activity

Observed database signals

Registration numbers95
Price-history records185
Products with price history34
Source records with multiple versions1
Latest MedInfoBase verification10 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

37 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Mikacin Amikacin 250 mg Injection 2mlx1’s 057358 PKR 89.62 PKR 44.81/mL 31% below median
Mikacin Amikacin 500 mg Injection 2mlx1’s 057359 PKR 169.74 PKR 84.87/mL 30% below median
Polyvee Ointment Polymyxin B + Bacitracin 10000 units/g + 500 units/g Ointment 10gm 019335 PKR 32.59 PKR 3.26/g Near median
Polyvee Ointment Polymyxin B + Bacitracin 10000 units/g + 500 units/g Ointment 20gm 019335 PKR 65.18 PKR 3.26/g Near median
Quinine Quinine dihydrochloride 300 mg Injection 2ml 013620 PKR 71.45 PKR 35.73/mL No comparator
Quinine Bisulphate Quinine bisulfate 300 mg Tablet 10x10 028336 PKR 291.97 PKR 2.92/tablet 8% above median
Quinine Bisulphate Quinine bisulfate 300 mg Tablet 200's 028336 PKR 543.19 PKR 2.72/tablet Near median
Quinine Bisulphate Quinine bisulfate 300 mg Tablet 100's 028336 PKR 271.60 PKR 2.72/tablet Near median
Venomox Moxifloxacin 400 mg Tablet 1x5’s 097611 PKR 645.04 PKR 129.01/tablet 29% below median
Vetran Trimethoprim 80 mg Tablet 20x10 028309 PKR 592.63 PKR 2.96/tablet Near median
Vetran Trimethoprim 80 mg Tablet 200 028309 PKR 592.63 PKR 2.96/tablet Near median
Vetran DS Sulfamethoxazole + Trimethoprim 160 mg + 800 mg Tablet 10x10 028310 PKR 583.80 PKR 5.84/tablet Near median
Vetran DS Sulfamethoxazole + Trimethoprim 160 mg + 800 mg Tablet 100's 028310 PKR 583.80 PKR 5.84/tablet Near median
Vio-Chlor Chloroquine 150 mg Tablet 30x10 030231 PKR 142.58 PKR 0.48/tablet Near median
Vio-Chlor Chloroquine 150 mg Tablet 1000 030231 PKR 377.52 PKR 0.38/tablet 21% below median
Vio-fung Griseofulvin 500 mg Tablet 2x10's 028337 PKR 237.65 PKR 11.88/tablet 50% below median
Vioflox-500 Levofloxacin 500 mg Tablet 10 ‘s 100606 PKR 396.53 PKR 39.65/tablet 50% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.